Journal List > Tuberc Respir Dis > v.68(4) > 1001488

TOOLS
Shin, Lee, Byun, Chang, Kim, Chang, Ahn, and Kim: The Clinical and Pathologic Features according to Expression of Acyl Protein Thioesterase-1 (APT1) in Stage I Non-small Cell Lung Cancer
Original Article
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2010; 68(4): 212-217.

Published online: 30 April 2010

DOI: https://doi.org/10.4046/trd.2010.68.4.212

The Clinical and Pathologic Features according to Expression of Acyl Protein Thioesterase-1 (APT1) in Stage I Non-small Cell Lung Cancer

Jung Ar Shin, M.D.1, Chang Ryul Lee, M.D.2, Min Kwang Byun, M.D.1, Yoon Soo Chang, M.D.1, Se Kyu Kim, M.D.1, Joon Chang, M.D.1, Chul Min Ahn, M.D.1, Hyung Jung Kim, M.D.1

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

2Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.

Address for correspondence: Hyung Jung Kim, M.D. Department of Internal Medicine, Gangnam Severance Hospital, 712, Eonju-ro, Gangnam-gu, Seoul 135-270, Korea. Phone: 82-2-2019-3309, Fax: 82-2-3463-3882, khj57@yuhs.ac

Received 9 March 2010       Accepted 31 March 2010

Copyright © 2010. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Abstract

Background

Acyl protein thioesterase-1 (APT1) is a cytosolic protein that may function in the depalmitoylation of numerous proteins, including the Ras family. However, the clinical role of depalmitoyl thioesterase in human cancer is not known. We evaluated the APT1 expression in lung cancer tissue and its clinicopathological findings according APT1 expression pattern.

Methods

APT1 expression was examined by immunohistochemistry in the tumor tissue from 79 patients, who had undergone curative surgical removal of the primary lesion; all patients had been diagnosed with stage I non-small cell lung cancer between 1993 and 2004, at Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Results

The APT1 expression was seen in 50 out of 79 (63.3%) cases. The positive APT1 expression was significantly related with histologic subtype and T stage, but was not influenced by differentiation. The positive APT1 expression was not significantly related to patient age, gender, or smoking history. The median follow-up duration was 10.0 years; the 5-year survival rate was 71.0%. The positive APT1 expression group showed significantly worse overall survival and worse disease-free survival without statistical significance.

Conclusion

We conclude that positive APT1 expression in stage I lung cancer after surgery is closely associated with overall survival. To evaluate APT1 as a prognostic marker in lung cancer, comprehensive studies on advanced stage cases are needed.

Keywords: Acyl protein thioesterase, Carcinoma, Non-Small-Cell Lung, Biological Markers

Figures and Tables

Figure 1
APT1 expression in lung cancer tissues. An adenocarcinoma has no APT1 expression (A), whereas other has strong (B; inset, ×400). Also squamous cell carcinoma shows no expression (C) vs. strong expression (D; inset, ×400). Most of bronchioloalveolar carcinoma (E) and large cell carcinoma (F) has no APT1 expression (×200) (Immunohistochemistry).
trd-68-212-g001
Figure 2
Survival analysis of stage I lung cancer patients according to APT1 expression. The positive expression of APT1 do not significantly influence disease-free survival (A) but showed worse overall survival (B) of lung cancer patients.
trd-68-212-g002
Table 1
Analysis of the patients with stage 1 NSCLC according to the expression status of APT1
trd-68-212-i001

NSCLC: non-small cell lung cancer; SCC: squamous cell carcinoma; BAC: bronchioloalveolar carcinoma; TNM: tumor-node-metastasis; CI: confidence interval.

*Mean±standard deviation, †p-value <0.05.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009. 59:225–249.
2. Subotic D, Mandaric D, Radosavljevic G, Stojsic J, Gajic M, Ercegovac M. Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study. World J Surg Oncol. 2009. 7:87.
3. Wang A, Dennis EA. Mammalian lysophospholipases. Biochim Biophys Acta. 1999. 1439:1–16.
4. Baekkeskov S, Kanaani J. Palmitoylation cycles and regulation of protein function (Review). Mol Membr Biol. 2009. 26:42–54.
5. Sugimoto H, Hayashi H, Yamashita S. Purification, cDNA cloning, and regulation of lysophospholipase from rat liver. J Biol Chem. 1996. 271:7705–7711.
6. Molina JR, Adjei AA. The Ras/Raf/MAPK Pathway. J Thorac Oncol. 2006. 1:7–9.
7. Riely GJ, Marks J, Pao W. KRAS Mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009. 6:201–205.
8. Quatela SE, Philips MR. Ras signaling on the Golgi. Curr Opin Cell Biol. 2006. 18:162–167.
9. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002. 4:343–350.
10. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001. 410:1111–1116.
11. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol. 2007. 128:100–108.
12. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005. 23:857–865.
TOOLS
Similar articles